Intracellular cholesterol accumulation and coenzyme Q10 deficiency in Familial Hypercholesterolemia. 2018

Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
Centro Andaluz de Biología del Desarrollo (CABD-CSIC-Universidad Pablo de Olavide), Centro de Investigación Biomédica en Red: Enfermedades Raras, Instituto de Salud Carlos III, Sevilla 41013, Spain.

Familial Hypercholesterolemia (FH) is an autosomal co-dominant genetic disorder characterized by elevated low-density lipoprotein (LDL) cholesterol levels and increased risk for premature cardiovascular disease. Here, we examined FH pathophysiology in skin fibroblasts derived from FH patients harboring heterozygous mutations in the LDL-receptor. Fibroblasts from FH patients showed a reduced LDL-uptake associated with increased intracellular cholesterol levels and coenzyme Q10 (CoQ10) deficiency, suggesting dysregulation of the mevalonate pathway. Secondary CoQ10 deficiency was associated with mitochondrial depolarization and mitophagy activation in FH fibroblasts. Persistent mitophagy altered autophagy flux and induced inflammasome activation accompanied by increased production of cytokines by mutant cells. All the pathological alterations in FH fibroblasts were also reproduced in a human endothelial cell line by LDL-receptor gene silencing. Both increased intracellular cholesterol and mitochondrial dysfunction in FH fibroblasts were partially restored by CoQ10 supplementation. Dysregulated mevalonate pathway in FH, including increased expression of cholesterogenic enzymes and decreased expression of CoQ10 biosynthetic enzymes, was also corrected by CoQ10 treatment. Reduced CoQ10 content and mitochondrial dysfunction may play an important role in the pathophysiology of early atherosclerosis in FH. The diagnosis of CoQ10 deficiency and mitochondrial impairment in FH patients may also be important to establish early treatment with CoQ10.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D011973 Receptors, LDL Receptors on the plasma membrane of nonhepatic cells that specifically bind LDL. The receptors are localized in specialized regions called coated pits. Hypercholesteremia is caused by an allelic genetic defect of three types: 1, receptors do not bind to LDL; 2, there is reduced binding of LDL; and 3, there is normal binding but no internalization of LDL. In consequence, entry of cholesterol esters into the cell is impaired and the intracellular feedback by cholesterol on 3-hydroxy-3-methylglutaryl CoA reductase is lacking. LDL Receptors,Lipoprotein LDL Receptors,Receptors, Low Density Lipoprotein,LDL Receptor,LDL Receptors, Lipoprotein,Low Density Lipoprotein Receptor,Low Density Lipoprotein Receptors,Receptors, Lipoprotein, LDL,Receptor, LDL,Receptors, Lipoprotein LDL
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D001259 Ataxia Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions. Coordination Impairment,Dyssynergia,Incoordination,Ataxia, Appendicular,Ataxia, Limb,Ataxia, Motor,Ataxia, Sensory,Ataxia, Truncal,Ataxy,Dyscoordination,Lack of Coordination,Tremor, Rubral,Appendicular Ataxia,Appendicular Ataxias,Ataxias,Ataxias, Appendicular,Ataxias, Limb,Ataxias, Motor,Ataxias, Sensory,Ataxias, Truncal,Coordination Impairments,Coordination Lack,Impairment, Coordination,Impairments, Coordination,Incoordinations,Limb Ataxia,Limb Ataxias,Motor Ataxia,Motor Ataxias,Rubral Tremor,Rubral Tremors,Sensory Ataxia,Sensory Ataxias,Tremors, Rubral,Truncal Ataxia,Truncal Ataxias
D014451 Ubiquinone A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals. Coenzyme Q

Related Publications

Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
April 2001, Neurology,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
April 2002, Nihon rinsho. Japanese journal of clinical medicine,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
May 2016, Deutsches Arzteblatt international,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
June 2008, The New England journal of medicine,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
January 1992, Duodecim; laaketieteellinen aikakauskirja,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
August 2001, Neurology,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
January 2007, Neurochemical research,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
March 2021, Neurogenetics,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
June 1974, Biochemical and biophysical research communications,
Juan M Suárez-Rivero, and Mario de la Mata, and Ana Delgado Pavón, and Marina Villanueva-Paz, and Suleva Povea-Cabello, and David Cotán, and Mónica Álvarez-Córdoba, and Irene Villalón-García, and Patricia Ybot-González, and Joaquín J Salas, and Ovidio Muñiz, and Mario D Cordero, and José A Sánchez-Alcázar
July 2014, Molecular syndromology,
Copied contents to your clipboard!